Literature DB >> 23628314

A replication study examining association of rs6983267, rs10090154, and rs1447295 common single nucleotide polymorphisms in 8q24 region with prostate cancer in Siberians.

Natalia A Oskina1, Ulyana A Boyarskikh2, Alexandr F Lazarev3, Valentina D Petrova3, Dmitry I Ganov3, Olga G Tonacheva4, Galina I Lifshits2, Maxim L Filipenko2.   

Abstract

INTRODUCTION: Multiple genetic studies have confirmed association of 8q24 variants with susceptibility to prostate cancer (CaP). However, the risk conferred in men living in Russia is unknown.
MATERIALS AND METHODS: In this work we studied the association of rs6983267, rs10090154, and rs1447295 single nucleotide polymorphisms (SNPs) with a risk of CaP development in men of Caucasoid descent living in the Siberian region of Russia. Three 8q24 SNPs were genotyped by real-time polymerase chain reaction in histologically confirmed CaP "cases" (n = 392) and clinically evaluated "controls" (n = 344). To evaluate the SNP effects on CaP susceptibility, odds ratio (OR) and confidence interval (CI) 95% were calculated. Allele and genotype frequencies in the groups were compared using logistic regression; differences were considered statistically significant if P<0.05.
RESULTS: We showed statistically significant association of the A allele of rs1447295 (OR [CI 95%] = 1.96 [1.37-2.81], P<0.0001) and the T allele of rs10090154 (OR [CI 95%] = 2.14 [1.41-3.26], P<0.0001) with CaP. The T-A rs10090154 to rs1447295 haplotype was also associated with CaP (OR [CI 95%] = 2.47 [1.59-3.85], P<0.0001). There was no significant association with the T allele of rs6983267: OR [CI 95%] = 0.9 [0.73-1.11], P> 0.05.
CONCLUSION: Thus, our investigation confirms the role of chromosomal region 8q24 in the development of CaP in the Russian population.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Prostate cancer; Region of chromosome 8q24; Russian; Single nucleotide polymorphisms (SNPs)

Mesh:

Year:  2013        PMID: 23628314     DOI: 10.1016/j.urolonc.2013.02.017

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

1.  Variants on 8q24 and prostate cancer risk in Chinese population: a meta-analysis.

Authors:  Xiao-Qiang Ren; Jian-Guo Zhang; Shi-Yong Xin; Tao Cheng; Liang Li; Wei-Hua Ren
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Association of single nucleotide polymorphism rs6983267 with the risk of prostate cancer.

Authors:  Yuan Yang; Wenjing Wang; Liangcai Zhang; Shihua Zhang; Guiyou Liu; Yingcui Yu; Mingzhi Liao
Journal:  Oncotarget       Date:  2016-05-03

Review 3.  Long noncoding RNA CCAT2 as a novel biomaker of metastasis and prognosis in human cancer: a meta-analysis.

Authors:  Dailian Wang; Zhicong Chen; Haidan Xu; Anbang He; Yuchen Liu; Weiren Huang
Journal:  Oncotarget       Date:  2017-05-24

4.  Association between 8q24 Gene Polymorphisms and the Risk of Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Ran Li; Zhiqiang Qin; Jingyuan Tang; Peng Han; Qianwei Xing; Feng Wang; Shuhui Si; Xiaolu Wu; Min Tang; Wei Wang; Wei Zhang
Journal:  J Cancer       Date:  2017-09-15       Impact factor: 4.207

5.  Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects.

Authors:  Man Zhu; Xue Wen; Xuefang Liu; Yingchao Wang; Chunzi Liang; Jiancheng Tu
Journal:  Oncotarget       Date:  2017-07-04

6.  Long noncoding RNA CCAT2 reduces chemosensitivity to 5-fluorouracil in breast cancer cells by activating the mTOR axis.

Authors:  Daoping Zhou; Juan Gu; Yueping Wang; Bing Luo; Mei Feng; Xuedong Wang
Journal:  J Cell Mol Med       Date:  2022-02-15       Impact factor: 5.310

7.  Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.

Authors:  Behnaz Beikzadeh; Seyed Abdolhamid Angaji; Maryam Abolhasani
Journal:  BMC Med Genet       Date:  2020-04-15       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.